An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia |
| |
| Authors: | Ibai Los-Arcos Joaquin Burgos Vicenç Falcó |
| |
| Affiliation: | 1. Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona , Barcelona, Spain !["ORCID]("//:0" "\"ORCID") https://orcid.org/0000-0001-8835-2702;2. Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona , Barcelona, Spain |
| |
| Abstract: | ABSTRACT Introduction Ceftolozane-tazobactam is a combination of a new cephalosporin, with activity similar to that of ceftazidime, and a known inhibitor of beta-lactamases. This compound shows excellent activity against most gram-negative organisms causative of hospital-acquired pneumonia (HAP) or ventilator-acquired pneumonia (VAP), including extended spectrum beta-lactamase (ESBL)-producing Enterobacterales and multidrug-resistant (MDR) Pseudomonas aeruginosa. |
| |
| Keywords: | Ceftolozane-tazobactam hospital-acquired pneumonia ventilator-acquired pneumonia multidrug-resistant organisms Pseudomonas aeruginosa |
|
|
!["ORCID]({"type":"image","src":"/templates/jsp/images/orcid.png"} "\"ORCID")
https://orcid.org/0000-0001-8835-2702;2. Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona , Barcelona, Spain